Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Anavex Life Sciences Corp AVXL

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer’s disease, Parkinson’s disease, and other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2 (MECP2). The Company’s product candidates include NAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066. ANAVEX 3-71 is a central nervous system (CNS) penetrable potential disease modifying treatment for cognitive impairments. ANAVEX 1-41 is a sigma-1 agonist.


NDAQ:AVXL - Post by User

Bullboard Posts
Post by R_J_on Oct 01, 2019 11:03am
186 Views
Post# 30181961

End of Month - September 2019

End of Month - September 2019End of the Month (EOM) report for September 2019.
-
AVXL closed on 09/30/2019 at US$3.16
AVXL closed on 08/30/2019 at US$2.64
AVXL closed on 07/05/2019 at US$2.56
-
This is a 19.7%, a 52-cent, gain for September.
-
S&P 500 Index, @ 2,976.7, gained 1.7% in September. [5.0% above its MA(200) @ 2,834.5]
-
Two Hundred Day Moving Average [MA(200)] stuff.
AVXL's  MA(200) ended September at $2.73
AVXL is now 15.8% above its MA(200).
-
News Releases on the AVXL Website in September
-
Use this link to see and read the all of September’s News Release.
-
End of the Month (EOM) report for September 2019.
-
AVXL closed on 09/30/2019 at US$3.16
AVXL closed on 08/30/2019 at US$2.64
AVXL closed on 07/05/2019 at US$2.56
-
This is a 19.7%, a 52-cent, gain for September.
-
S&P 500 Index, @ 2,976.7, gained 1.7% in September. [5.0% above its MA(200) @ 2,834.5]
-
Two Hundred Day Moving Average [MA(200)] stuff.
AVXL's  MA(200) ended September at $2.73
AVXL is now 15.8% above its MA(200).
-
News Releases on the AVXL Website in September
-
Use this link to see and read the all of September’s News Release.
-
End of the Month (EOM) report for September 2019.
-
AVXL closed on 09/30/2019 at US$3.16
AVXL closed on 08/30/2019 at US$2.64
AVXL closed on 07/05/2019 at US$2.56
-
This is a 19.7%, a 52-cent, gain for September.
-
S&P 500 Index, @ 2,976.7, gained 1.7% in September. [5.0% above its MA(200) @ 2,834.5]
-
Two Hundred Day Moving Average [MA(200)] stuff.
AVXL's  MA(200) ended September at $2.73
AVXL is now 15.8% above its MA(200).
-
News Releases on the AVXL Website in September
-
Use this link to see and read the all of September’s News Release.
-
https://www.anavex.com/2019/09/
-
RJ
Bullboard Posts